MCID: ACT113
MIFTS: 40

Acute Myeloblastic Leukemia with Maturation

Categories: Rare diseases, Blood diseases, Cancer diseases

Aliases & Classifications for Acute Myeloblastic Leukemia with Maturation

MalaCards integrated aliases for Acute Myeloblastic Leukemia with Maturation:

Name: Acute Myeloblastic Leukemia with Maturation 53 59
Acute Myeloblastic Leukemia M2 53 59
Aml M2 53 59
Acute Myeloblastic Leukemia Type 2 53
Acute Myeloid Leukemia 73
Lam M2 53

Characteristics:

Orphanet epidemiological data:

59

Classifications:



External Ids:

Orphanet 59 ORPHA98834
UMLS via Orphanet 74 C1879321
ICD10 via Orphanet 34 C92.0
UMLS 73 C1879321

Summaries for Acute Myeloblastic Leukemia with Maturation

MalaCards based summary : Acute Myeloblastic Leukemia with Maturation, also known as acute myeloblastic leukemia m2, is related to leukemia and hepatocellular carcinoma. An important gene associated with Acute Myeloblastic Leukemia with Maturation is MIR181A1HG (MIR181A1 Host Gene), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 M2 is a subtype of AML (Acute Myeloid... more...

Related Diseases for Acute Myeloblastic Leukemia with Maturation

Graphical network of the top 20 diseases related to Acute Myeloblastic Leukemia with Maturation:



Diseases related to Acute Myeloblastic Leukemia with Maturation

Symptoms & Phenotypes for Acute Myeloblastic Leukemia with Maturation

GenomeRNAi Phenotypes related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.6 KIT FLT3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.6 FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.6 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.6 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.6 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.6 FLT3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.6 FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.6 KIT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.6 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.6 FLT3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.6 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.6 FLT3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.6 KIT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.6 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.6 FLT3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.6 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.6 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.6 KIT
19 Decreased substrate adherent cell growth GR00193-A-1 9.46 KIT
20 Decreased substrate adherent cell growth GR00193-A-2 9.46 KIT
21 Decreased substrate adherent cell growth GR00193-A-4 9.46 FLT3 KIT
22 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.96 FLT3 KIT

MGI Mouse Phenotypes related to Acute Myeloblastic Leukemia with Maturation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.8 FLT3 KIT NPM1

Drugs & Therapeutics for Acute Myeloblastic Leukemia with Maturation

Drugs for Acute Myeloblastic Leukemia with Maturation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1 52-24-4 5453
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antilymphocyte Serum Phase 4,Phase 2
9
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
10
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
11
Mesna Approved, Investigational Phase 3 3375-50-6 598
12
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
13
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
15
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
16
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
17
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
18
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
19
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
20
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
21
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
22
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
23
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
24
Hydroxyurea Approved Phase 3 127-07-1 3657
25
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
27
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
28
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
29
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
30
Carmustine Approved, Investigational Phase 3 154-93-8 2578
31
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
32
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
33
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
34
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
35
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
37
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
38 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
39
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
40 Interleukin-2 Phase 3,Phase 1,Phase 2
41 Analgesics Phase 3,Phase 2,Phase 1
42 Gemtuzumab Phase 2, Phase 3,Phase 3,Phase 1
43 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Dermatologic Agents Phase 3,Phase 2,Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
46 Vaccines Phase 3
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antibodies Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 182)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
3 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
4 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
6 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
7 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
9 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
10 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
11 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
12 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
13 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
14 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
15 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
16 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
17 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
18 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
19 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
20 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
21 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
22 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
23 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
24 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
25 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
26 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
27 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
28 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
29 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
30 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
31 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
32 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
33 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
34 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
35 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
36 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
37 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
38 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
39 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
40 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
41 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
42 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
43 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
44 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
45 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
46 Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
47 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib
48 Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia Completed NCT00602771 Phase 2 tipifarnib;etoposide
49 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed NCT00462605 Phase 2 entinostat;sargramostim
50 S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00093418 Phase 2 tipifarnib

Search NIH Clinical Center for Acute Myeloblastic Leukemia with Maturation

Genetic Tests for Acute Myeloblastic Leukemia with Maturation

Anatomical Context for Acute Myeloblastic Leukemia with Maturation

MalaCards organs/tissues related to Acute Myeloblastic Leukemia with Maturation:

41
Myeloid, Bone, Bone Marrow, Lung, Prostate

Publications for Acute Myeloblastic Leukemia with Maturation

Articles related to Acute Myeloblastic Leukemia with Maturation:

# Title Authors Year
1
T(1;21;8)(p34;q22;q22): a novel variant of t(8;21) in acute myeloblastic leukemia with maturation. ( 20949334 )
2011
2
t(8;21;8)(p23;q22;q22): a new variant form of t(8;21) translocation in acute myeloblastic leukemia with maturation. ( 11699421 )
2001
3
Translocation(8;20;21)(q22;q13;q22) in acute myeloblastic leukemia with maturation: a variant form of t(8;21). ( 9460498 )
1998

Variations for Acute Myeloblastic Leukemia with Maturation

ClinVar genetic disease variations for Acute Myeloblastic Leukemia with Maturation:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NC_000001.11: g.198807802C> A single nucleotide variant Pathogenic rs9660525 GRCh38 Chromosome 1, 198807802: 198807802
2 NC_000001.11: g.198807802C> A single nucleotide variant Pathogenic rs9660525 GRCh37 Chromosome 1, 198776931: 198776931
3 MIR181A1HG NR_040073.1(MIR181A1HG): n.364-18748G> A single nucleotide variant Pathogenic rs12406470 GRCh38 Chromosome 1, 198826991: 198826991
4 MIR181A1HG NR_040073.1(MIR181A1HG): n.364-18748G> A single nucleotide variant Pathogenic rs12406470 GRCh37 Chromosome 1, 198796120: 198796120
5 MIR181A1HG NR_040073.1(MIR181A1HG): n.363+1862C> A single nucleotide variant Pathogenic rs60639710 GRCh38 Chromosome 1, 198898549: 198898549
6 MIR181A1HG NR_040073.1(MIR181A1HG): n.363+1862C> A single nucleotide variant Pathogenic rs60639710 GRCh37 Chromosome 1, 198867678: 198867678
7 MIR181A1HG NR_040073.1(MIR181A1HG): n.363+1456C> T single nucleotide variant Pathogenic rs10800597 GRCh38 Chromosome 1, 198898955: 198898955
8 MIR181A1HG NR_040073.1(MIR181A1HG): n.363+1456C> T single nucleotide variant Pathogenic rs10800597 GRCh37 Chromosome 1, 198868084: 198868084
9 MIR181A1HG NR_040073.1(MIR181A1HG): n.363+26A> G single nucleotide variant Pathogenic rs10800598 GRCh38 Chromosome 1, 198900385: 198900385
10 MIR181A1HG NR_040073.1(MIR181A1HG): n.363+26A> G single nucleotide variant Pathogenic rs10800598 GRCh37 Chromosome 1, 198869514: 198869514

Expression for Acute Myeloblastic Leukemia with Maturation

Search GEO for disease gene expression data for Acute Myeloblastic Leukemia with Maturation.

Pathways for Acute Myeloblastic Leukemia with Maturation

GO Terms for Acute Myeloblastic Leukemia with Maturation

Cellular components related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.62 FLT3 KIT

Biological processes related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.58 FLT3 KIT NPM1
2 protein autophosphorylation GO:0046777 9.54 FLT3 KIT
3 peptidyl-tyrosine phosphorylation GO:0018108 9.52 FLT3 KIT
4 positive regulation of MAPK cascade GO:0043410 9.51 FLT3 KIT
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.49 FLT3 KIT
6 negative regulation of signal transduction GO:0009968 9.48 FLT3 KIT
7 hemopoiesis GO:0030097 9.46 FLT3 KIT
8 positive regulation of kinase activity GO:0033674 9.43 FLT3 KIT
9 positive regulation of cell proliferation GO:0008284 9.43 FLT3 KIT NPM1
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.37 FLT3 KIT
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.32 FLT3 KIT
12 positive regulation of MAP kinase activity GO:0043406 9.16 FLT3 KIT
13 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 8.96 FLT3 KIT
14 myeloid progenitor cell differentiation GO:0002318 8.62 FLT3 KIT

Molecular functions related to Acute Myeloblastic Leukemia with Maturation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.5 FLT3 KIT NPM1
2 protein tyrosine kinase activity GO:0004713 9.37 FLT3 KIT
3 MAP kinase kinase kinase activity GO:0004709 9.26 FLT3 KIT
4 mitogen-activated protein kinase kinase binding GO:0031434 9.16 FLT3 KIT
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.96 FLT3 KIT
6 growth factor binding GO:0019838 8.62 FLT3 KIT

Sources for Acute Myeloblastic Leukemia with Maturation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....